Compare Twist Bioscience Corp (TWST) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Workday Inc — how do they compare? Twist Bioscience Corp trades at $158.89 (market cap $10.08B), while Workday Inc trades at $189.97 (market cap $45.26B). The key difference: Workday Inc is far larger — about 4.5× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Workday Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Workday Inc for 38 Days on average.
| TWST | WDAY | |
|---|---|---|
Market Cap | $10.08B | $45.26B |
Volume | 4,229,037 | 2,342,190 |
Sector | Health | Technology |
52-Week High | $205.00 | $245.67 |
52-Week Low | $25.45 | $112.55 |
Typical Hold Time | 27 Days | 38 Days |
Enterprise Value | $10.01B | $45.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Workday (WDAY) trades at $184.26, down 1.23% on the day amid a broader tech selloff, with a bearish technical signal. The company shows strong revenue growth, reaching $8.45B in 2025, and has consistently beaten earnings estimates. Recent strategic moves include AI product launches and a 2.5% headcount reduction aimed at efficiency. Analyst consensus is bullish with a $202.92 price target, but negative net cash flow and high valuation ratios present risks.
The outlook for WDAY is mixed; strong fundamentals and AI integration offer growth potential, but high P/E of 38.25 and recent layoffs signal execution risks. Investors should weigh robust analyst support against valuation concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
